Yuya Seko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4147574/publications.pdf

Version: 2024-02-01

304368 223531 2,279 61 22 46 h-index citations g-index papers 64 64 64 2993 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. Laboratory Investigation, 2022, 102, 281-289.	1.7	19
2	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. Journal of Gastroenterology, 2022, 57, 90-98.	2.3	6
3	Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clinical Journal of Gastroenterology, 2022, 15, 467-474.	0.4	5
4	Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach. Scientific Reports, 2022, 12, 5050.	1.6	3
5	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 48-60.	4.2	25
6	Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines, 2022, 10, 901.	1.4	6
7	Medical checkup data analysis method based on LiNGAM and its application to nonalcoholic fatty liver disease. Artificial Intelligence in Medicine, 2022, 128, 102310.	3.8	2
8	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. Hepatology International, 2021, 15, 366-379.	1.9	71
9	SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSK‑3β signaling pathway in esophageal squamous cell carcinoma. Oncology Letters, 2021, 21, 269.	0.8	2
10	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis. Cancers, 2021, 13, 1515.	1.7	7
11	The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. Genes, 2021, 12, 628.	1.0	8
12	Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNÎ ³ /STAT1 Signaling in Hepatocellular Carcinoma Cells. Frontiers in Oncology, 2021, 11, 707473.	1.3	6
13	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radical Biology and Medicine, 2021, 177, 391-403.	1.3	12
14	Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. Journal of Gastroenterology, 2021, 56, 1045-1061.	2.3	18
15	Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. Frontiers in Oncology, 2021, 11, 758549.	1.3	6
16	Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-Î ² 1/SMAD Signaling and Autophagy in Hepatic Stellate Cells. International Journal of Molecular Sciences, 2021, 22, 13354.	1.8	9
17	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. Journal of Gastroenterology, 2020, 55, 428-440.	2.3	50
18	Serum soluble sialic acidâ€binding immunoglobulinâ€like lectinâ€7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2020, 50, 466-477.	1.8	7

#	Article	IF	CITATIONS
19	FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2020, 21, 171.	1.8	16
20	PPARÎ \pm agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. Scientific Reports, 2020, 10, 19578.	1.6	7
21	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics, 2020, 10, 579.	1.3	21
22	The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. Diagnostics, 2020, 10, 842.	1.3	2
23	Effect of pemafibrate on fatty acid levels and liver enzymes in nonâ€alcoholic fatty liver disease patients with dyslipidemia: A singleâ€arm, pilot study. Hepatology Research, 2020, 50, 1328-1336.	1.8	23
24	Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma. Anticancer Research, 2020, 40, 3953-3960.	0.5	5
25	Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. Cancers, 2020, 12, 754.	1.7	18
26	Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. Diagnostics, 2020, 10, 86.	1.3	8
27	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158, 1611-1625.e12.	0.6	575
28	Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 1686-1692.	1.9	21
29	Diagnostic accuracy of FibroScanâ€AST score to identify nonâ€alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with nonâ€alcoholic fatty liver disease: Comparison between M and XL probes. Hepatology Research, 2020, 50, 831-839.	1.8	32
30	The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals. Internal Medicine, 2020, 59, 1811-1817.	0.3	0
31	Reply to: Sarcopenia definition in patients with NAFLD. Journal of Gastroenterology, 2019, 54, 298-298.	2.3	0
32	Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology, 2019, 54, 160-170.	2.3	20
33	Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1473-1492.	1.1	4
34	Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Research, 2019, 39, 5149-5156.	0.5	57
35	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1626-1632.	1.4	19
36	Clinical and pathological features of sarcopeniaâ€related indices in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2019, 49, 627-636.	1.8	16

#	Article	IF	Citations
37	Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver. Biomedical Reports, 2019, 11, 191-198.	0.9	2
38	Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIBâ€4 index. Hepatology Research, 2019, 49, 473-478.	1.8	19
39	The genetic backgrounds in nonalcoholic fatty liver disease. Clinical Journal of Gastroenterology, 2018, 11, 97-102.	0.4	38
40	Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatology Research, 2018, 48, E42-E51.	1.8	23
41	Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. Journal of Gastroenterology, 2018, 53, 140-151.	2.3	57
42	Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. Journal of Gastroenterology, 2018, 53, 438-448.	2.3	24
43	Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 835-843.	1.1	60
44	Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. International Journal of Oncology, 2018, 53, 237-245.	1.4	35
45	Accuracy of nonâ€invasive scoring systems for diagnosing nonâ€alcoholic steatohepatitisâ€related fibrosis: Multicenter validation study. Hepatology Research, 2018, 48, 1099-1107.	1.8	22
46	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Scientific Reports, 2018, 8, 10434.	1.6	32
47	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. Journal of Gastroenterology, 2018, 53, 1216-1224.	2.3	68
48	Hepatic nucleotide binding oligomerization domain â€ like receptors pyrin domainâ€containing 3 inflammasomes are associated with the histologic severity of nonâ€alcoholic fatty liver disease. Hepatology Research, 2017, 47, 1459-1468.	1.8	20
49	Effect of 12â€week dulaglutide therapy in Japanese patients with biopsyâ€proven nonâ€alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatology Research, 2017, 47, 1206-1211.	1.8	64
50	Novel antidiabetic medications for nonâ€elcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research, 2017, 47, 266-280.	1.8	53
51	Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with nonâ€alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatology Research, 2017, 47, 1072-1078.	1.8	72
52	Development of hepatocellular carcinoma in Japanese patients with biopsyâ€proven nonâ€alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatology Research, 2017, 47, 1083-1092.	1.8	61
53	Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in nonâ€alcoholic fatty liver disease. Hepatology Research, 2017, 47, 721-730.	1.8	16
54	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterology, 2017, 17, 96.	0.8	65

Yuya Seko

#	Article	IF	CITATION
55	Association of coronary artery calcification with liver fibrosis in <scp>Japanese</scp> patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2016, 46, 1107-1117.	1.8	17
56	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. Journal of Gastroenterology, 2016, 51, 586-596.	2.3	49
57	Serum alanine aminotransferase predicts the histological course of nonâ€alcoholic steatohepatitis in <scp>J</scp> apanese patients. Hepatology Research, 2015, 45, E53-61.	1.8	46
58	Predictors of malignancies and overall mortality in <scp>J</scp> apanese patients with biopsyâ€proven nonâ€alcoholic fatty liver disease. Hepatology Research, 2015, 45, 728-738.	1.8	28
59	Drugâ€induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. Hepatology Research, 2015, 45, E156-60.	1.8	5
60	Lower levels of insulinâ€like growth factorâ€1 standard deviation score are associated with histological severity of nonâ€alcoholic fatty liver disease. Hepatology Research, 2015, 45, 771-781.	1.8	64
61	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma. American Journal of Gastroenterology, 2012, 107, 253-261.	0.2	230